机译:VEGFR2在肝细胞癌中的预后意义和潜在治疗靶点
Key Laboratory of AntibodyTechnique of Ministry of Health,Department of Pathology,Nanjing Medical University,Nanjing, China,Surgical ComprehensiveLaboratory, Department ofPathology, Affiliated Hospital ofNantong University, Nantong,Jiangsu Province, China;
Key Laboratory of AntibodyTechnique of Ministry of Health,Department of Pathology,Nanjing Medical University,Nanjing, China;
Key Laboratory of AntibodyTechnique of Ministry of Health,Department of Pathology,Nanjing Medical University,Nanjing, China;
Key Laboratory of AntibodyTechnique of Ministry of Health,Department of Pathology,Nanjing Medical University,Nanjing, China;
Key Laboratory of AntibodyTechnique of Ministry of Health,Department of Pathology,Nanjing Medical University,Nanjing, China;
Key Laboratory of AntibodyTechnique of Ministry of Health,Department of Pathology,Nanjing Medical University,Nanjing, China;
Key Laboratory of AntibodyTechnique of Ministry of Health,Department of Pathology,Nanjing Medical University,Nanjing, China,Huadong Medical Institute ofBiotechniques, Nanjing, Jiangsu,China;
机译:真核翻译起始因子5A(eIF5A)在肝细胞癌中的预后意义和治疗潜力。
机译:KIFC1,一种新的潜在的肝细胞癌预后因素和治疗靶标
机译:乙型或丙型肝炎相关肝细胞癌中的非编码RNA:潜在的诊断和预后标志物和治疗靶标
机译:Alphaab-Crystallin基因在肝细胞癌中的表达及其预后意义
机译:基于表型的具有构象特异性抑制剂的筛选显示P38γ和δ作为肝细胞癌的治疗靶标。
机译:EG5作为预后生物标志物和肝细胞癌的潜在治疗靶标
机译:真核翻译起始因子5a(eIF5a)在肝细胞癌中的预后意义和治疗潜力